Abstract
This single-group study investigated the immunogenicity and safety of a booster dose of the recently licensed live attenuated chimeric Japanese encephalitis vaccine in 50 healthy children (1-5 years old) who were primed with the live attenuated SA14-14-2 vaccine. A strong anamnestic response was induced 28 days postbooster: geometric mean titer, 9144 (95% confidence interval: 7365-11353); and seroprotection rate, 49 of 49 (100%) children.
Trial registration:
ClinicalTrials.gov NCT02526550.
Publication types
-
Clinical Trial, Phase IV
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antibodies, Neutralizing / blood
-
Antibodies, Viral / blood*
-
Child, Preschool
-
Encephalitis Viruses, Japanese / immunology*
-
Encephalitis, Japanese / prevention & control
-
Humans
-
Immunization, Secondary
-
Infant
-
Japanese Encephalitis Vaccines / administration & dosage
-
Japanese Encephalitis Vaccines / adverse effects
-
Japanese Encephalitis Vaccines / immunology*
-
Thailand
-
Vaccines, Attenuated / administration & dosage
-
Vaccines, Attenuated / adverse effects
-
Vaccines, Attenuated / immunology*
Substances
-
Antibodies, Neutralizing
-
Antibodies, Viral
-
Japanese Encephalitis Vaccines
-
Vaccines, Attenuated
Associated data
-
ClinicalTrials.gov/NCT02526550